PGM1
Phosphoglucomutase-1
Also known as: PGM1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P36871
- Gene
- PGM1
- Ensembl
- ENSG00000079739
- Chromosome
- 1
- Canonical length
- 562 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Cytosol
OverviewNCBI Gene
The protein encoded by this gene is an isozyme of phosphoglucomutase (PGM) and belongs to the phosphohexose mutase family. There are several PGM isozymes, which are encoded by different genes and catalyze the transfer of phosphate between the 1 and 6 positions of glucose. In most cell types, this PGM isozyme is predominant, representing about 90% of total PGM activity. In red cells, PGM2 is a major isozyme. This gene is highly polymorphic. Mutations in this gene cause glycogen storage disease type 14. Alternativley spliced transcript variants encoding different isoforms have been identified in this gene.[provided by RefSeq, Mar 2010]
Canonical amino-acid sequenceUniProt
562 residues, UniProt reviewed canonical sequence.
>P36871|PGM1
1 MVKIVTVKTQ AYQDQKPGTS GLRKRVKVFQ SSANYAENFI QSIISTVEPA QRQEATLVVG
61 GDGRFYMKEA IQLIARIAAA NGIGRLVIGQ NGILSTPAVS CIIRKIKAIG GIILTASHNP
121 GGPNGDFGIK FNISNGGPAP EAITDKIFQI SKTIEEYAVC PDLKVDLGVL GKQQFDLENK
181 FKPFTVEIVD SVEAYATMLR SIFDFSALKE LLSGPNRLKI RIDAMHGVVG PYVKKILCEE
241 LGAPANSAVN CVPLEDFGGH HPDPNLTYAA DLVETMKSGE HDFGAAFDGD GDRNMILGKH
301 GFFVNPSDSV AVIAANIFSI PYFQQTGVRG FARSMPTSGA LDRVASATKI ALYETPTGWK
361 FFGNLMDASK LSLCGEESFG TGSDHIREKD GLWAVLAWLS ILATRKQSVE DILKDHWQKY
421 GRNFFTRYDY EEVEAEGANK MMKDLEALMF DRSFVGKQFS ANDKVYTVEK ADNFEYSDPV
481 DGSISRNQGL RLIFTDGSRI VFRLSGTGSA GATIRLYIDS YEKDVAKINQ DPQVMLAPLI
541 SIALKVSQLQ ERTGRTAPTV ITLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PGM1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.2
- Highest tissue expression
- 1,461 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 1,461 nTPM
- tongue: 736 nTPM
- liver: 262 nTPM
- heart muscle: 174 nTPM
- pancreas: 112 nTPM
- adipose tissue: 107 nTPM
Single-cell type
- myonuclei: 368 nCPM
- hepatocytes: 306 nCPM
- extravillous trophoblasts: 301 nCPM
- breast lactating cells: 250 nCPM
- thymic myoid cells: 226 nCPM
- granulosa cells: 219 nCPM
Immune cell
- eosinophil: 49 nTPM
- myeloid DC: 48 nTPM
- basophil: 46 nTPM
- NK-cell: 44 nTPM
- gdT-cell: 41 nTPM
- neutrophil: 39 nTPM
Brain region
- choroid plexus: 81 nTPM
- medulla oblongata: 63 nTPM
- thalamus: 47 nTPM
- midbrain: 42 nTPM
- basal ganglia: 41 nTPM
- cerebellum: 41 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PGM1.
Disease | AllUniProt
Conditions PGM1 is implicated in, by any mechanism.
- Congenital disorder of glycosylation 1T (CDG1T) MIM:614921
Disease | GeneticClinVar
45 pathogenic / likely-pathogenic of 531 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- PGM1-congenital disorder of glycosylation
- PGM1-related disorder
- Inborn genetic diseases
- Congenital disorder of glycosylation
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.32
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.23
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- carbohydrate metabolic process
- galactose catabolic process via UDP-galactose, Leloir pathway
- gluconeogenesis
- glucose metabolic process
- glycogen catabolic process
- glycolytic process
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Alpha-D-phosphohexomutase superfamily
- Alpha-D-phosphohexomutase, alpha/beta/alpha domain I
- Alpha-D-phosphohexomutase, alpha/beta/alpha domain II
- Alpha-D-phosphohexomutase, alpha/beta/alpha domain III
- Alpha-D-phosphohexomutase, alpha/beta/alpha I/II/III
- Alpha-D-phosphohexomutase, conserved site
- Alpha-D-phosphohexomutase, C-terminal domain superfamily
- Phosphoglucomutase
- Phosphoglucomutase/phosphomannomutase, alpha/beta/alpha domain I
- Phosphoglucomutase/phosphomannomutase, alpha/beta/alpha domain II
- Phosphoglucomutase/phosphomannomutase, alpha/beta/alpha domain III
- Phosphoglucomutase-1, C-terminal domain
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PGM1 as an antibody target. Whether an autoantibody or antibody against PGM1 could matter depends on whether native PGM1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PGM1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PGM1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...